Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -2.55% is 92% above its 5-year average of -32.12%, near the high end of its 5-year range (-78.91%–0.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 80.21% above its 12-month average of -12.90%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -2.55%.
RETURN ON EQUITY (ROE)
-2.55%
RETURN ON EQUITY (ROE) AVG TTM
-12.90%
RETURN ON EQUITY (ROE) AVG 3Y
-18.20%
RETURN ON EQUITY (ROE) AVG 5Y
-32.12%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+80.21%
CURRENT VS 3Y AVG
+85.98%
CURRENT VS 5Y AVG
+92.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+93.93%
vs the sector median at left
Dianthus Therapeutics, Inc.
Market Cap
$4.78B
Return on Equity (ROE)
-2.55%
TTM Avg
-12.90%
3Y Avg
-18.20%
5Y Avg
-32.12%
Market Cap
$4.73B
Return on Equity (ROE)
-38.51%
TTM Avg
-50.16%
3Y Avg
-65.11%
5Y Avg
-61.13%
Market Cap
$4.83B
Return on Equity (ROE)
N/A
TTM Avg
-23.20%
3Y Avg
-51.91%
5Y Avg
-56.25%
Market Cap
$4.84B
Return on Equity (ROE)
-11.92%
TTM Avg
-22.12%
3Y Avg
-20.62%
5Y Avg
-23.54%
Market Cap
$4.70B
Return on Equity (ROE)
3.43%
TTM Avg
-1.67%
3Y Avg
-7.64%
5Y Avg
-9.04%
Market Cap
$4.64B
Return on Equity (ROE)
16.63%
TTM Avg
15.37%
3Y Avg
15.09%
5Y Avg
11.91%
Market Cap
$4.60B
Return on Equity (ROE)
6.24%
TTM Avg
-11.62%
3Y Avg
-98.18%
5Y Avg
-98.18%
Market Cap
$4.96B
Return on Equity (ROE)
-79.37%
TTM Avg
-38.23%
3Y Avg
-43.73%
5Y Avg
-49.41%
Market Cap
$5.06B
Return on Equity (ROE)
3.38%
TTM Avg
1.14%
3Y Avg
-0.67%
5Y Avg
-0.98%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dianthus Therapeutics, Inc. (DNTH) | $4.78B | -2.55% | -12.90% | -18.20% | -32.12% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.73B | -38.51% | -50.16% | -65.11% | -61.13% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.83B | N/A | -23.20% | -51.91% | -56.25% |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.84B | -11.92% | -22.12% | -20.62% | -23.54% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.70B | 3.43% | -1.67% | -7.64% | -9.04% |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | 16.63% | 15.37% | 15.09% | 11.91% |
| BillionToOne, Inc. (BLLN)vs › | $4.60B | 6.24% | -11.62% | -98.18% | -98.18% |
| Erasca, Inc. (ERAS)vs › | $4.96B | -79.37% | -38.23% | -43.73% | -49.41% |
| Waystar Holding Corp. (WAY)vs › | $5.06B | 3.38% | 1.14% | -0.67% | -0.98% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | 8.67% | 8.42% | 7.80% | 5.80% |
ROE
-2.6%
ROA
-2.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -2.55% |
| 2026-03-31 | -0.94% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | -23.12% |
| 2025-06-30 | -37.86% |
| 2025-03-31 | -30.65% |
| 2024-12-31 | -24.11% |
| 2024-09-30 | -19.86% |
| 2024-06-30 | -15.82% |
| 2024-03-31 | -13.47% |
| 2023-12-31 | -25.79% |
| 2023-09-30 | -24.17% |
| 2023-06-30 | -48.43% |
| 2023-03-31 | -54.56% |
| 2022-12-31 | -78.91% |
| 2022-09-30 | -54.26% |
| 2022-06-30 | -56.71% |
| 2022-03-31 | -50.66% |
| 2021-12-31 | -41.20% |
| 2021-09-30 | -36.91% |
| 2021-06-30 | -34.63% |
| 2021-03-31 | -56.11% |
| 2020-12-31 | -52.07% |
| 2020-09-30 | -50.46% |
| 2020-06-30 | -47.91% |
| 2020-03-31 | -65.35% |
| 2019-12-31 | -54.37% |
| 2019-09-30 | -43.47% |
| 2019-06-30 | -36.33% |
| 2019-03-31 | -45.66% |
| 2018-12-31 | -39.49% |
| 2018-09-30 | -30.59% |
| 2018-06-30 | -23.09% |
| 2018-03-31 | -103.09% |
| 2017-12-31 | -70.53% |
